Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13069088 | 0.92 | CTSK (0.51) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13570964 | 0.90 | CYP1A2 (0.50) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13570965 | 0.90 | CYP1A2 (0.50) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12572284 | 0.88 | CTSK (0.45) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9196011 | 0.88 | CTSK (0.50) | CTSKCTSSTDP1ATMP2RY2 | |
| SCHEMBL17600320 | 0.88 | CTSK (0.52) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17600321 | 0.88 | CTSK (0.52) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11506791 | 0.88 | CTSK (0.49) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13069729 | 0.88 | CTSK (0.50) | CTSKCTSSTDP1ATMP2RY2 | |
| SCHEMBL2070869 | 0.87 | CTSK (0.49) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9017645-B2 | Homoglutamic acid derivatives | PIRAMAL IMAGING SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-9017645-B2 | Homoglutamic acid derivatives | PIRAMAL IMAGING SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20130071327-A1 | HOMOGLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-03-21 | — | — | US | disclosed |
| US-20130071327-A1 | HOMOGLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-03-21 | — | — | US | disclosed |
| US-20130034497-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130034497-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-02-07 | — | — | US | disclosed |
| EP-2520556-A1 | Radiolabeled amino acids for diagnostic imaging | Bayer Pharma Aktiengesellschaft (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-2501416-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | Piramal Imaging SA (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061154-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011057986-A1 | HOMOGLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034497-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | GLUL, GCG, GLS | CTSK 1448/4885CTSS 2695/4885CYP1A2 3870/4885 |
| US-20130071327-A1 | HOMOGLUTAMIC ACID DERIVATIVES | FGB, GGCT, RIMKLA | CTSK 483/4885CTSS 958/4885CYP1A2 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.